-
Trump threatens to destroy Iran's largest gas field
-
Doncic and James power Lakers over Rockets as win streak hits seven
-
Inter continue Serie A title hunt ahead of Italy's date with World Cup destiny
-
Strait of Hormuz blockage drives up Gulf food bills
-
Ahead of election, Danish city mirrors country's challenges
-
Wild possum shelters with plush toys in Australian airport shop
-
Iran missile fire kills 3 Palestinians in West Bank, foreign worker in Israel
-
Asian Games cruise ship and wooden huts will be 'unique experience'
-
Pacific nations fear fuel shortages as Middle East war sends oil prices soaring
-
World indoor athletics championships: five stand-out events
-
Crude prices surge, stocks sink as Iran warns of regional energy strikes
-
'No oil, no money': Orban brings Ukraine standoff to Brussels
-
Mideast energy shock rattles eurozone rate-setters
-
Scotland's Laidlaw extends tenure as Hurricanes coach
-
Messi scores 900th career goal but Miami crash out
-
Japan coach says Australia 'massive favourites' in Asian Cup final
-
Iran targets Gulf energy sites after gas field strike
-
Director plans to put Val Kilmer back on screen thanks to AI
-
Social media addiction trial jury deliberations continue
-
Messi scores 900th career goal in Inter Miami cup clash
-
Barcelona, Liverpool, Bayern and Atletico reach Champions League quarter-finals
-
Tudor impressed by 'improved' Spurs despite Champions League exit
-
PSG will not relish Liverpool reunion, says Slot
-
Kane says Bayern 'don't fear anyone' ahead of Real clash
-
Venezuelan leader sacks defense minister, a Maduro stalwart
-
Kane and Bayern swat aside Atalanta to set up Real clash
-
Thailand's new parliament set to elect Anutin as PM
-
Atletico survive Spurs scare to reach Champions League quarters
-
Liverpool thrash Galatasaray to reach Champions League quarters
-
Music popstar will.i.am meshes AI and 'micromobility'
-
US Fed Chair says 'no intention' of leaving board while probe ongoing
-
US stocks fall on latest oil price surge as Fed lifts inflation forecast
-
Iran targets Gulf energy sites after intel chief killed
-
Costa Rica closes Havana embassy, tells Cuba to withdraw diplomats
-
NY's New Museum returns contemporary to heart of Manhattan
-
Cesar Chavez, icon of US labor movement, accused of serial sex abuse: report
-
Barcelona demolish Newcastle 7-2 to reach Champions League quarters
-
US Fed raises inflation outlook over 'uncertain' Iran war impact
-
Trump nominee for Homeland Security chief grilled at fiery Senate hearing
-
First international aid convoy arrives in crisis-hit Cuba
-
Eight killed during Rio police operation, including drug kingpin
-
Iran suffers new blow as Israel kills intel chief
-
Slovakia curbs diesel sales, ups prices for foreigners
-
Oscar-winner Sean Penn meets troops in frontline Ukraine
-
Thousands rally in Istanbul to mark year since mayor's arrest
-
WNBA, players union agree 'transformative' labor deal: official
-
US Fed holds rates unchanged over 'uncertain' Iran war implications
-
Senegal govt calls for investigation into Cup of Nations decision
-
From Faraja to Sepah: Iran's multiple security forces
-
Billionaire Dyson buys 50 percent stake in Bath rugby
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Schubert--BTB